Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655064 in Chronic Primary Immune Thrombocytopenic Purpura
NCT02009761Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2013
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 655064 in immune thrombocytopenic purpura (ITP), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Patients With Response in Platelet Count at 12 weeks. Started Dec 2013; status: terminated.
02
Drugs
BI 655064
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT02009761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009761.